Johnson&Johnson Innovative Medicine	**Data Sharing Request Due Diligence Assessment**

General Information	
YODA Project (Protocol) ID:	2025-0460
Date Proposal Received by YODA Project:	23-Jun-2025
Product Name(s):	Bapineuzumab
Condition(s) Studied:	Alzheimer Disease
NCT Numbers(s), Protocol Number(s) and Title(s):	1. NCT00574132 - **ELN115727-301** A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non-Carriers **2.** NCT00575055 - **ELN115727-302** A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers

Proposal Review	
Question 1: The clinical trial data from the study/studies listed above were previously identified and approved as being available for a data sharing request. **Is there any reason why the study/studies listed should no longer be shared?**	No
Comments if 'Yes':	
Question 2: On review of the proposal, is there any data that has been requested that may be **missing** from the clinical database?	No
Comments if 'Yes':	
Question 3: Is a similar analysis underway, or completed and pending disclosure by J&J?	No
Comments if 'Yes':	